Although not approved for human consumption, KLOW marks an exciting time in the continued investment and development of peptide therapy as a future treatment
Future studies should incorporate mechanism-relevant biological markers, including serum BDNF to index neurotrophic signaling, inflammatory markers such as CRP and IL-6, measures of HPA-axis activity such as the cortisol awakening response, and neuroimaging markers (e.g., fMRI-based assessments of hippocampal connectivity), to more precisely characterize treatment response and patient stratification
Easy-to-use injection kits shipped to your door
Childrens autism metabolome project participants The Childrens Autism Metabolome Project (CAMP, ClinicalTrials.gov Identifier: NCT02548442) study enrolled 1,102 children, ages 1848 months, across 8 clinical sites from August, 2015 through January, 2018
Explore the full complete guide to peptides for foundational research information